Imedex® is an industry leader in providing certified, independent continuing medical education to health care professionals.

August 4-5, 2017

Philadelphia, PA

Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care

A Luncheon Symposium at US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes


Friday, August 4, 2017

12:35 pm – 2:35 pm
Philadelphia Marriott West
111 Crawford Avenue
West Conshohocken, Pennsylvania

Chair
Elizabeth O. Hexner, MD, MSTR

Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Continuing Education

Physicians

ACCMEImedex®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Imedex®, LLC designates this live educational activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

Maintenance of Certification (MOC)
Successful completion of this CME activity enables a participant to earn up to 1.5 MOC points the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is Imedex’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC Points.

Who Should Attend
This live educational activity is designed to meet the educational needs of hematologists, medical oncologists and other healthcare professionals (physicians, physicians-in-training, oncology nurses, pharmacists, physicians’ assistants, etc.) who are involved and/or interested in the treatment of patients with targetable MPN.

Objectives
Upon successful completion of this educational activity, participants should be better able to:

  • Implement revised diagnostic criteria in patients with polycythemia vera
  • Analyze the molecular abnormalities associated with polycythemia vera
  • Formulate optimal strategies for use of initial and second line therapies to treat polycythemia vera
  • Evaluate data on investigational and emerging therapies for polycythemia management

Faculty

Elizabeth O. Hexner, MD, MSTR
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Brady Lee Stein, MD, MHS
Northwestern Feinberg University School of Medicine
Chicago, Illinois

Srdan Verstovsek, MD, PhD
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Agenda

12:50 pm

Welcome and pre-activity polling via ARS
Elizabeth O. Hexner, MD, MSTR

1:00 pm

Prognostication and initiation of therapy in PV: Do we have it right?
Brady Lee Stein, MD, MHS

1:20 pm

When to move from hydroxyurea to second-line therapy
Elizabeth O. Hexner, MD, MSTR

1:40 pm

Ropeginterferon, welcome to the US
Srdan Verstovsek, MD, PhD

2:00 pm

Panel discussion, recap of key points
Moderator: Elizabeth O. Hexner, MD, MSTR

2:10 pm

Post-activity polling via ARS
Elizabeth O. Hexner, MD, MSTR

2:20 pm

Adjournment

Support

The following company has provided an educational grant in support of this symposium:

Incyte Corporation

Registration

The Treatment Dilemmas in Polycythemia Vera: Leveraging Evidence and Clinical Experience to Improve Patient Care symposium will be presented at the US Focus on Myeloproliferative Neoplasms and Myelodysplastic Syndromes meeting and is open to attendees registered for that meeting. There is no additional fee to attend the symposium and pre-registration for the symposium is not required. Registration includes admittance to all scientific sessions, conference materials, processing of certificates of participation or continuing education, and all event functions including meals as specified in the agenda.